New diagnostic and therapeutic tools
against multidrug resistant tumours

Efficacy validation of new therapeutic tools against pre-clinical models of MDR tumours

The main goal of WG3 is the evaluation at a preclinical level of the efficacy of synthetic and natural compounds -and their formulations- developed by WG2. Compunds will be tested against the variety of samples (MDR cells lines, CSCs, primary samples derived from patients studied by WG1) in in vitro and in vivo; against the pro-invasive behaviour of MDR cells; on the activation of the host immune system against MDR tumors; and on the process of the intercellular transfer of the MDR phenotype by targeting proper biomarkers carried by MDR tumor-released microvesicles.

WG3 Members

Total 62 participants
An WOUTERS
Ana Bela SARMENTO-RIBEIRO
Ana CIPAK GASPAROVIC
Ana DAMJANOVIC
Ana PODOLSKI-RENIC
Ana VUJAČIĆ NIKEZIĆ
Anamaria BROZOVIC
Andreas CONSTANTINOU
Angélica FIGUEROA
Aylin KOSËLER
Bart ROMAN
Cekdar VAKIF AHMETOGLU
Chiara RIGANTI
Christiana NEOPHYTOU
Cosmin-Teodor MIHAI
Crina TIRON
Cristina XAVIER
Elena GAZZANO
Elisabeth PÉREZ-RUIZ
Flavio RIZZOLIO
Francois VALLETTE
Gabriella SPENGLER
Graca SOVERAL
Helena OLIVEIRA
Hülya AYAR KAYALY
Ignacio OCHOA GARRIDO
Inese CAKSTINA
Ioannis P. TROUGAKOS
Iris Chiara SALAROGLIO
Ivana MATIC
Jelena GRAHOVAC
Jeremy PULLICINO
Jitka VIKTOROVA
Joanna KOPECKA
Jorrit ENSERINK
Kjetil TASKEN
Lisa OLIVER
M. Helena VASCONCELOS
Maria Cecilia CARPINELLA
Maria José UMBELINO FERREIRA
Marija DJORDJIC
Marilina GARCÍA
Mauro ALINI
Miglė PAŠKEVIČIŪTĖ
Milica PESICGoogle Scholar
Mirza SULJAGIC
Monica Suarez KORSNES
Muriel CUENDET
Nuray ERIN
Oscar LOPEZ LOPEZGoogle Scholar
Ozan SELVI
Petra HEFFETER
Radka VACLAVIKOVA
Sandor KASAS
Sündüs ERBAS CAKMAK
Tatjana SRDIC-RAJIC
Teodora-Alexa STRATULAT
Tijana STANKOVIC
Tiziano SERRA
Vilma PETRIKAITE
Walter BERGER
Yehuda ASSARAF